Correspondence |

Parkinsonism and Cancer

Glen E. Kisby, PhD; Peter S. Spencer, PhD, FRCPath
JAMA Neurol. 2013;70(3):414-415. doi:10.1001/jamaneurol.2013.1283.
Text Size: A A A
Published online


Kareus and colleagues1 propose genetic links to explain an association between Parkinson disease (PD plus other parkinsonian disorders) and certain cancers, specifically melanoma and prostate cancer, across 3 generations in Utah. Closely knit populations, such as those in Utah, might also share etiologically relevant transgenerational exposures; witness Guam parkinsonism-dementia, which associates with foods containing the cycad toxin cycasin, the glucoside of methylazoxymethanol.2 The carcinogenic and neurotoxic properties of methylazoxymethanol are both mediated by DNA damage, changes in microRNA expression, and gene perturbation, the outcome ranging from proliferation for cycling cells (tumorigenesis) to degeneration for postmitotic neurons.3 Pathways in cancer, melanogenesis, and prostate cancer are 3 of the top 9 perturbed cell-signaling pathways in the brains of mice treated systemically with methylazoxymethanol.4 Methylazoxymethanol disrupts the PI3K-AKT-mTOR pathway, which is implicated in both melanogenesis and prostate cancer.5 The methylazoxymethanol metabolite formaldehyde, which is elevated in prostate cancer,6 is a member of the 1-carbon pool, use of which is impacted by the enzyme activity of methylenetetrahydrofolate reductase (MHTFR), and MTHFR polymorphisms are linked to the risk for PD, prostate cancer, and skin cancer, including melanoma.79

Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours

First Page Preview

View Large
First page PDF preview





Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Comment


Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Topics
PubMed Articles

The Rational Clinical Examination
Make the Diagnosis: Parkinsonism

The Rational Clinical Examination
Original Article: Does This Patient Have Parkinson Disease?